Treatment of chronic hepatitis C in hemodialysis patients

Hepatology

Volumn 48, Issue 5, 2008, Pages 1690-1699

  Berenguer, Marina ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CALCINEURIN INHIBITOR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA2B INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON ALFA-2B;

ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DEPRESSION; DERMATITIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GRAFT FAILURE; HEMATOLOGIC DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINURIA; HEPATITIS C; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL DECISION MAKING; MONOTHERAPY; MYALGIA; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; ARTICLE; CHRONIC KIDNEY FAILURE; HOSPITAL ADMISSION; METHODOLOGY; PREVALENCE; RENAL REPLACEMENT THERAPY;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PREVALENCE; RENAL DIALYSIS; WAITING LISTS;

EID: 56149114504     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22545     Document Type: Review

References (60)

1. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. HEPATOLOGY 2002;36:3-10.
2. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis 2004;24:69-77.
3. Guideline 3: Preventing HCV transmission in hemodialysis units. Kidney Int 2008;73(Suppl 109):S46-S52.
4. Kamar N, Izopet J, Alric L, Guilbeaud-Frugier C, Rostaing L. Hepatitis C virus-related kidney disease: An overview. Clin Nephrol 2008;69:149-160.
5. Bino T, Madar Z, Gertler A, Rosenberg H. The kidney is the main site of interferon degradation. J Interferon Res 1982;2:301-308.
6. Uchihara M, Izumi N, Sakai Y, Yauchi T, Miyake S, Sakai T, et al. Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon. Nephron 1998;80:51-56.
7. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42: 1109-1115.
8. PEG-intron® (peginterferon alfa-2b) powder for injection. Kenilworth, NJ: Schering Corporation; 2005.
9. Pegasys® (peginterferon alfa-2a). Nutley, NJ: Hoffmann-La Roche Inc.; 2004.
10. Rebetol® (ribavirin, USP) capusules and oral solution. Kenilworth, NJ: Schering Corporation; 2004.
11. Rocha CM, Perez RM, Ferreira AP, Carvalho-Filho RJ, Pace FH, Silva IS, et al. Efficacy and tolerance of interferon-α in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006;26:305-310.
12. Degos F, Pol S, Chaix ML, Laffitte V, Buffet C, Bernard PH, et al. The tolerance and efficacy of interferon-α in haemodialysis patients with HCV infection: A multicentre, prospective study. Nephrol Dial Transplant 2001; 16:1017-1023.
13. Chan TM, Wu PC, Lau JYN, Lok ASF, Lai CL, Cheng IKP. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997;12:1414-1419.
14. Rivera M, Gentil MA, Sayago M, Gonzalez Roncero F, Trigo C, Algarra G, et al. Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant. Transplant Proc 2005;37:1424-1425.
15. Artan R, Akcam M, Yilmaz A, Kocacik D. Interferon alpha monotherapy for chronic hepatitis C viral infection in thalassemics and hemodialysis patients. J Chemother 2005;17:651-655.
16. Espinosa M, Rodriguez M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Lopez-Rubio F, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001;55:220-226.
17. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: Study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005;100:c133-c139.
18. Ozdemir FN, Akcay A, Sezer S, Boyacioglu S, Ozdemir BH, Arat Z, et al. A six-year follow-up after interferon-alpha monotherapy for chronic hepatitis C infection in hemodialysis patients. Ren Fail 2004;26:583-588.
19. Grgurevic I, Vince A, Buljevac M, Banic M, Jeren-Strujic B, Kes P, et al. Efficacy of interferon-α in the treatment of chronic hepatitis C in dialysis patients: Two therapeutic protocols compared. Nephron Clin Pract 2006; 103:c8-c11.
20. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071-1081.
21. Russo MW, Goldsweig CD, Jacobson IM, Brown RS Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: An analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610-1615.
22. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
23. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
24. Covic A, Maftei I-D, Mardare NGI, Ionita-Radu F, Totolici C, Tuta L, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: Results from a large, multicenter audit. J Nephrol 2006;19:794-801.
25. Russo MW, Ghalib R, Sigal S, Joshi V. Randomized trial of pegylated interferon α-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006;21:437-443.
26. Chan TM, Ho SKN, Tang CSO, Tse KC, Lam MF, Lai KN, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology (Carlton) 2007;12:11-17.
27. Sporea I, Popescu A, Sirli R, Golea O, Totolici C, Danila M, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006;12:4191-4194.
28. Annicchiarico BE, Siciliano M. Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Aliment Pharmacol Ther 2004;20:123-124.
29. Amarapurkar DN, Patel ND, Kirpalani AL. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop Gastroenterol 2007;28:16-18.
30. Casanovas-Taltavull T, Baliellas C, Llobet M, Cruzado JM, Castellote J, Casanova A, et al. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007;39:2125-2127.
31. Tan SS, Abu Hassan MR, Abdullah A, Ooi BP, Rampal S, Korompis T, et al. Treatment of hemodialysis (HD) patients with chronic hepatitis C (CHC) using an escalating dose regimen of pegylated interferon (PEG-IFN) alfa-2b [Abstract]. HEPATOLOGY 2007;46(Suppl):363A-364A.
32. Kokoglu OF, Ucmak H, Hosoglu S, Cetinkaya A, Kantarceken B, Buyukbese MA, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006;21:575-580.
33. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J Viral Hepat 2001;8:287-292.
34. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-321.
35. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004;36:1831-1834.
36. Deltenre P, Canval V, Provo F, Glowacki F, Dharancy S, Ali HB, et al. Pegylated interferon and ribavirin in haemodialyzed patients with chronic hepatitis C: A prospective study. Presented at: 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27-31, 2006; Boston, MA.
37. Tan ACITL, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: Results of a pilot study. Nephrol Dial Transplant 2001;16:193-195.
38. Luxon BA, Muir AJ, Heneghan MA. Safety and tolerability of pegylated interferon with or without low dose ribavirin for treatment of hepatitis C in hemodialysis [Abstract]. HEPATOLOGY 2005;42(Suppl):703A-704A.
39. Hakim W, Sheikh S, Inayat I, Bia M, Caldwell C, Jain D, et al. Initial HCV response in patients with end stage renal disease treated with combination pegylated interferon alfa-2a and ribavirin. Presented at: Digestive Disease Week; May 20-25, 2006; Los Angeles, CA.
40. van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23: 721-725.
41. Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008;31:295-302.
42. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998; 46:563-570.
43. Rendina M, Schena A, Castellaneta NM, Losito F, Amoruso AC, Stallone G, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007;46:768-774.
44. Molmenti EP, Jain AB, Shapiro R, Scantlebury V, Lee R, Totsuka E, et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. Transplantation 2001;71:267-271.
45. Kendrick EA, McVicar JP, Kowdley KV, Bronner MP, Emond MJ, Alpers CE, et al. Renal disease in hepatitis C-positive liver transplant recipients. Transplantation 1997;63:1287-1293.
46. Jain AB, Eghtesad B, Venkataramanan R, Fontes PA, Kashyap R, Dvorchik I, et al. Ribavirin dose modi.cation based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002;8:1007-1013.
47. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008;49:274-287.
48. Weclawiack H, Kamar N, Mehrenberger M, Guilbeau-Frugier C, Modesto A, Izopet J, et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 2008;23:1043-1047.
49. Montalbano M, Pasulo L, Sonzogni A, Remuzzi G, Colledan M, Strazzabosco M. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. J Clin Gastroenterol 2007;41:216-220.
50. Tokumoto T, Tanabe K, Ishikawa N, Simizu T, Oshima T, Noguchi S, et al. Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc 1999;31: 2887-2889.
51. Telegdy L, Gorog D, Horanyi M, Schaff Z. Severe relapse of hepatitis C following liver transplantation; successful treatment with a combination of interferon-alpha and ribavirin. Orv Hetil 1999;140:1891-1893.
52. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano T, Casanova A, Perez JL, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001;96:1170-1177.
53. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78:853-857.
54. Karaca C, Besisik F, Akyuz F, Dincer D, Sever MS, Okten A. Ribavirin treatment in patients with chronic hepatitis C infection who had renal transplantation. Dig Surg 2005;22:113.
55. Calanca LN, Fehr T, Jochum W, Fischer-Vetter J, Mullhaupt B, Wuthrich RP, et al. Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 2007;39:54-58.
56. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231-264.
57. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
58. Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Predictors of sustained virological response to interferon-based treatment in hemodialysis patients with chronic hepatitis C virus infection - a patient level meta-analysis [Abstract]. HEPATOLOGY 2007;46(Suppl):368A.
59. Guideline 1: Detection and evaluation of HCV in CKD. Kidney Int 2008; 73(Suppl 109):S10-S19.
60. Guideline 2: Treatment of HCV infection in patients with CKD. Kidney Int 2008;73(Suppl 109):S20-S45.